According to FutureWise analysis, the IVD Antibodies market in 2023 was US$4.3 billion, and is expected to reach US$7.7 billion by 2031 at a CAGR of 7.1. The significant growth of the IVD antibodies market is primarily driven by the increasing demand for early and accurate disease diagnostics, especially in oncology and infectious diseases. Technological advancements in immunoassay platforms and the rising adoption of point-of-care testing are also contributing to market expansion. Furthermore, the aging global population and a growing awareness of preventive healthcare are driving the demand for antibody-based in vitro diagnostic (IVD) tests.
In vitro diagnostics are commonly used for disease screening, therapeutic monitoring, and ensuring blood is safe for transfusions. Due to the increasing prevalence of chronic and infectious diseases worldwide, as well as the necessity of diagnosing chronic diseases early to receive proper treatment, IVD antibodies are in high demand. IVD antibodies are unique diagnostic tools in clinical diagnostics and research. As a result, they are now a required component of many diagnostic assays used to diagnose chronic diseases such as cancer, tuberculosis, and HIV. The IVD antibodies, in addition to detecting diseases at an early stage, allow medical professionals to initiate treatment. Immunonephelometric and sandwich ELISA are two immunological methods that extensively utilize IVD antibodies.
Antibodies are frequently used in IVD testing to identify and measure specific target molecules. They include cytokines that can be used to detect an inflammatory or autoimmune condition, bacterial or viral antigens that can be used to determine the presence of an infection, and various biomarkers for cancer, cardiovascular disease, or neurological disorders. A wide variety of sample types may accurately detect even low-abundance analytes owing to antibodies' excellent specificity and sensitivity. It's crucial to understand that IVD-grade antibodies are distinct from those that are exclusively intended for research purposes. Since IVD antibodies are frequently employed in a clinical context, they are subject to several licensing procedures to ensure the safety and effectiveness of the product. The IVD tests that use antibodies include lateral flow immunoassays for evaluating urine, saliva, or milk samples, ELISAs to analyse material such as blood or serum, and IHC analysis of tissue sections.
FutureWise Market Research has published a report that provides an insightful analysis of IVD antibodies market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, the IVD antibodies market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.